Research programme: transplant rejection therapy - Borean PharmaAlternative Names: IL-2 alpha receptor antagonist - Borean Pharma
Latest Information Update: 09 Aug 2007
At a glance
- Originator Borean Pharma
- Mechanism of Action Interleukin 2 receptor alpha subunit antagonists; Interleukin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Transplant rejection in Denmark (unspecified route)
- 25 Feb 2004 Preclinical trials in Transplant rejection in Denmark (unspecified route)